SymBio Pharmaceuticals Limited

TSE:4582 Stock Report

Market Cap: JP¥9.1b

SymBio Pharmaceuticals Management

Management criteria checks 1/4

SymBio Pharmaceuticals' CEO is Fuminori Yoshida, appointed in Mar 2005, has a tenure of 19.75 years. directly owns 2.57% of the company’s shares, worth ¥234.76M. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Key information

Fuminori Yoshida

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure19.8yrs
CEO ownership2.6%
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06
SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11
Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09
Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18
If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

CEO

Fuminori Yoshida (75 yo)

19.8yrs

Tenure

Mr. Fuminori Yoshida serves as President, Chief Executive Officer and Chief Operating Officer of Takeda Bio Development Center Limited. Mr. Yoshida founded SymBio Pharmaceuticals Limited in March 2005 and...

Leadership Team

NamePositionTenureCompensationOwnership
Fuminori Yoshida
CEO, President19.8yrsno data2.57%
¥ 234.8m
Takaaki Fukushima
Executive VP & Corporate Officerno datano datano data
Koji Fukushima
Corporate Officer & Chief Medical Officerno datano datano data
Yoshiharu Torikai
Corporate Officerno datano datano data
Masahiko Okuno
Corporate Officer1.8yrsno datano data
Hiroyuki Horita
Corporate Officer1.9yrsno datano data

1.9yrs

Average Tenure

Experienced Management: 4582's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Fuminori Yoshida
CEO, President19.8yrsno data2.57%
¥ 234.8m
Robert Lewis
Member of Scientific Advisory Boardno datano datano data
Tsutomu Takeuchi
Member of Scientific Advisory Boardno datano datano data
Toshio Suda
Member of Scientific Advisory Boardno datano datano data
Tatsutoshi Nakahata
Member of Scientific Advisory Boardno datano datano data
Makoto Ogawa
Member of Scientific Advisory Boardno datano datano data
Toshio Heike
Member of Scientific Advisory Boardno datano datano data
Shigetoshi Matsumoto
Independent Outside Directorno datano data0.049%
¥ 4.5m
Shinji Nakao
Member of Scientific Advisory Boardno datano datano data
Kiyoshi Watanabe
Outside Independent Director2.8yrsno datano data
Bruce David Cheson
Independent Outside Directorno datano datano data
Eiji Ebinuma
Independent Outside Director3.8yrsno datano data

3.8yrs

Average Tenure

75yo

Average Age

Experienced Board: 4582's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 02:00
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SymBio Pharmaceuticals Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathaniel CallowayEdison Investment Research
Kiyokazu YamazakiIchiyoshi Research Institute Inc.